BioCentury
ARTICLE | Emerging Company Profile

Abata: engineering targeted Treg cell therapies with TCRs

Emerging Company Profile: Third Rock launches Abata with $95M series A to develop targeted Treg cell therapies for autoimmune disorders

June 23, 2021 11:20 AM UTC


Access this Article

BCIQ Company Profiles

ElevateBio LLC